Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighte...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnet, Megan B., Cooper, Wendy A., Boyer, Michael J., Kao, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024943/
https://www.ncbi.nlm.nih.gov/pubmed/29904031
http://dx.doi.org/10.3390/jcm7060151
_version_ 1783336169629548544
author Barnet, Megan B.
Cooper, Wendy A.
Boyer, Michael J.
Kao, Steven
author_facet Barnet, Megan B.
Cooper, Wendy A.
Boyer, Michael J.
Kao, Steven
author_sort Barnet, Megan B.
collection PubMed
description Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.
format Online
Article
Text
id pubmed-6024943
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60249432018-07-09 Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms Barnet, Megan B. Cooper, Wendy A. Boyer, Michael J. Kao, Steven J Clin Med Review Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice. MDPI 2018-06-14 /pmc/articles/PMC6024943/ /pubmed/29904031 http://dx.doi.org/10.3390/jcm7060151 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Barnet, Megan B.
Cooper, Wendy A.
Boyer, Michael J.
Kao, Steven
Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
title Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
title_full Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
title_fullStr Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
title_full_unstemmed Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
title_short Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
title_sort immunotherapy in non-small cell lung cancer: shifting prognostic paradigms
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024943/
https://www.ncbi.nlm.nih.gov/pubmed/29904031
http://dx.doi.org/10.3390/jcm7060151
work_keys_str_mv AT barnetmeganb immunotherapyinnonsmallcelllungcancershiftingprognosticparadigms
AT cooperwendya immunotherapyinnonsmallcelllungcancershiftingprognosticparadigms
AT boyermichaelj immunotherapyinnonsmallcelllungcancershiftingprognosticparadigms
AT kaosteven immunotherapyinnonsmallcelllungcancershiftingprognosticparadigms

Ejemplares similares